Positive DEP HER2-Lu preclinical data support Phase 1 entry
Filed with ASX · · 5 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- DEP radiopharmaceutical data supports patent application
- FDA confirms path to DEP HER2 first-in-human study
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- AGM Chair address and CEO presentation
Later from Starpharma
- DEP milestone triggers partner option fee
- Quarterly Activities Report and Appendix 4C
- Fully Underwritten Entitlement Offer to Raise $32 Million
- Entitlement Offer Investor Presentation
- Successful Completion of $32 million Entitlement Offer
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma